Effectiveness of fludarabine in end-stage prolymphocytic leukemia.
Doorduijn
J K
JK
Michiels
J J
JJ
D000368:Aged; D000740:Anemia / Q000139:chemically induced; D015703:Antigens, CD / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001803:Blood Transfusion; D002699:Chlorambucil / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D015463:Leukemia, Prolymphocytic / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D013156:Splenectomy; D013921:Thrombocytopenia; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D015703:Antigens, CD; D000970:Antineoplastic Agents; D002699:Chlorambucil; D014740:Vidarabine; C024352:fludarabine